Literature DB >> 1636385

Conjunctival malignant melanoma in Sweden 1969-91.

S Seregard1, E Kock.   

Abstract

Clinical information, follow-up and histopathological parameters of the primary lesions were assessed for all (45) individuals with conjunctival malignant melanomas in Sweden presenting during a 22.5 year period (1969 to mid 1991). The annual incidence of conjunctival malignant melanoma in Sweden was 0.0240 per 100,000. On average, two new cases were diagnosed each year (population 8.6 million in 1991). Sixty-two per cent of the lesions recurred, but re-growth in itself was not correlated to reduced survival. The actuarial 10-year survival proportion using life-table analysis was 70%. A significantly reduced survival due to tumour-related death was noted in patients with tumours with high mitotic indices, many epithelioid cells and in lesions exceeding 10 mm in diameter. Other factors that may influence survival are presented in the context of previous reports. The present policy in Sweden for treating patients with malignant melanoma of the conjunctiva is outlined and discussed.

Entities:  

Mesh:

Year:  1992        PMID: 1636385     DOI: 10.1111/j.1755-3768.1992.tb08566.x

Source DB:  PubMed          Journal:  Acta Ophthalmol (Copenh)        ISSN: 0001-639X


  25 in total

1.  Conjunctival melanoma.

Authors:  Carol L Shields
Journal:  Br J Ophthalmol       Date:  2002-02       Impact factor: 4.638

2.  Chemosensitivity of conjunctival melanoma cell lines to target-specific chemotherapeutic agents.

Authors:  Henrike Westekemper; Michael Freistuehler; Norbert Bornfeld; Klaus-Peter Steuhl; Max Scheulen; Ralf A Hilger
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-07-11       Impact factor: 3.117

3.  Cell growth and p53 expression in primary acquired melanosis and conjunctival melanoma.

Authors:  S Seregard
Journal:  J Clin Pathol       Date:  1996-04       Impact factor: 3.411

Review 4.  Conjunctival melanoma in Southwestern Nigeria: a case series and review of literature.

Authors:  Oluyemi Fasina; Olayiwola A Oluwasola
Journal:  Int Ophthalmol       Date:  2017-06-19       Impact factor: 2.031

Review 5.  Advances in the management of conjunctival melanoma.

Authors:  Gargi K Vora; Hakan Demirci; Brian Marr; Prithvi Mruthyunjaya
Journal:  Surv Ophthalmol       Date:  2016-06-16       Impact factor: 6.048

6.  Conjunctival melanoma: association of cyclooxygenase-2 tumor expression to prognosis.

Authors:  Rita Pinto-Proença; Mariana Santos; Cristina Fonseca; Júlia Fernandes; Maria Filomena Gaspar; Rui Proença
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-01-02       Impact factor: 3.117

7.  Expression of matrix metalloproteinase (MMP)-2, MMP-9, and tissue inhibitor of MMP (TIMP)-1 in conjunctival melanomas and clinical implications.

Authors:  Hyoung Kyun Kim; Seoung Wan Chae; Kyung In Woo; Yoon-Duck Kim
Journal:  Jpn J Ophthalmol       Date:  2010-06-25       Impact factor: 2.447

Review 8.  Systemic BRAF/MEK Inhibitors as a Potential Treatment Option in Metastatic Conjunctival Melanoma.

Authors:  Joel M Mor; Ludwig M Heindl
Journal:  Ocul Oncol Pathol       Date:  2016-12-08

9.  Topical mitomycin C chemotherapy for conjunctival melanoma and PAM with atypia.

Authors:  P T Finger; G Czechonska; S Liarikos
Journal:  Br J Ophthalmol       Date:  1998-05       Impact factor: 4.638

10.  Topical treatment options for conjunctival neoplasms.

Authors:  Jonathan W Kim; David H Abramson
Journal:  Clin Ophthalmol       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.